NCT01678807View on ClinicalTrials.gov

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

PHASE1CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Rhinitis, Allergic, PerennialRhinitis, Allergic, Nonseasonal
Interventions
BIOLOGICAL

MK-8237 6 DU

BIOLOGICAL

MK-8237 12 DU

BIOLOGICAL

Placebo

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

ALK-Abelló A/S

INDUSTRY

NCT01678807 - Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008) | Biotech Hunter | Biotech Hunter